Leap Therapeutics, Inc.
NASDAQ:LPTX
0.3999 (USD) • At close April 25, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | 0 | 0 | 1.5 | 1.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0.427 | 0.415 | 0 | 0 | 0.776 | 0.049 | 0.048 | 0.025 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.427 | -0.415 | 1.5 | 1.5 | -0.776 | -0.049 | -0.048 | -0.025 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 57.211 | 73.234 | 44.965 | 32.16 | 20.423 | 24.366 | 21.074 | 22.503 | 23.292 | 15.369 | 15.542 | 9.303 | 7.168 |
| General & Administrative Expenses
| 12.846 | 13.807 | 11.798 | 10.766 | 9.616 | 9.085 | 8.921 | 9.849 | 4.229 | 5.72 | 4.711 | 4.567 | 1.507 |
| Selling & Marketing Expenses
| 0 | -0.427 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 12.846 | 13.38 | 11.798 | 10.766 | 9.616 | 9.085 | 8.921 | 9.849 | 4.229 | 5.72 | 4.711 | 4.567 | 1.507 |
| Other Expenses
| 0 | 0 | -2.051 | -1.226 | -0.231 | -0.132 | 0.756 | 0 | 3.12 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 70.057 | 86.614 | 54.712 | 41.7 | 29.808 | 33.319 | 29.995 | 32.352 | 27.521 | 21.089 | 20.253 | 13.87 | 8.675 |
| Operating Income
| -70.057 | -87.041 | -56.763 | -41.426 | -28.539 | -33.451 | -30.751 | -32.352 | -27.521 | -21.089 | -20.916 | -13.87 | -8.799 |
| Operating Income Ratio
| 0 | 0 | 0 | -27.617 | -19.026 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 3.087 | 5.627 | 2.314 | 0.815 | 1.023 | 0.548 | 7.633 | 2.468 | 1.889 | 9.039 | -4.504 | -4.305 | 1.043 |
| Income Before Tax
| -66.97 | -81.414 | -54.449 | -40.611 | -27.516 | -32.903 | -23.118 | -29.884 | -25.632 | -20.951 | -25.42 | -18.175 | -7.756 |
| Income Before Tax Ratio
| 0 | 0 | 0 | -27.074 | -18.344 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -0.585 | 0 | 0.147 | -0.024 | -0.002 | -0.003 | 0.02 | -0.157 | 4.353 | 0.152 | 0.031 | 0.149 | 0 |
| Net Income
| -67.789 | -81.414 | -54.596 | -40.587 | -27.514 | -32.9 | -23.138 | -29.727 | -25.632 | -21.103 | -25.451 | -18.324 | -7.756 |
| Net Income Ratio
| 0 | 0 | 0 | -27.058 | -18.343 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -1.81 | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.36 | -32.45 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| EPS Diluted
| -1.81 | -3.98 | -4.82 | -4.73 | -4.64 | -14.57 | -16.05 | -32.35 | -27.29 | -12.37 | -21.45 | -24.62 | -10.42 |
| EBITDA
| -70.057 | -80.987 | -53.98 | -40.014 | -26.809 | -32.104 | -23.05 | -29.715 | -24.374 | -11.921 | -19.729 | -13.23 | -6.983 |
| EBITDA Ratio
| 0 | 0 | 0 | -26.676 | -17.873 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |